Oxford Biomedica
Our goal is to become an integrated, self-financing gene and cell therapy business.Using our unique LentiVector® delivery platform, we have created a valuable portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders.